AMPKa2 Identified as Key Regulator of Amino Acid Insufficiency in Alzheimer's Disease

Strategic Insights -

Recent research has shed light on the role of AMPKa2 in transducing amino acid insufficiency signals to protein synthesis, providing new insights into the pathogenesis of Alzheimer's disease (AD). The study, conducted at Huashan Hospital in Shanghai, China, found that AMPKa2 specifically detects low amino acid levels and inhibits protein synthesis, which is a key contributor to AD-like symptoms in mice. This discovery has significant implications for the development of therapeutic strategies for AD.

Key Takeaways:

  • AMPKa2 is a specific amino acid abundance detector for protein synthesis, identifying low amino acid levels and inhibiting protein synthesis.
  • The study found that low amino acid levels, high protein levels, and reduced phosphorylation of AMPKa threonine 172 (p-T172) are observed in blood samples in patients with Alzheimer's disease (AD) from a cohort of 1,000,000 Chinese individuals.
  • Loss of AMPKa2, but not its counterpart AMPKa1, recaptures these observations and induces AD-like cognitive dysfunction in mice.
  • The mechanism underlying this process involves the phosphorylation of AMPKa2 at T172 by the general control non-repressible 2 (GCN2) kinase, independent of AMP and fructose 1,6-bisphosphate.
  • Activation of AMPK by metformin, AICAR, and branched-chain amino acid (BCAA) or protein restriction prevents AD-like symptoms in mice through a2-p-T172-dependent mechanisms.
  • The study identifies AMPKa2 as a potential therapeutic target for the development of treatments for AD.

Statistics:

  • 1,000,000: The number of Chinese individuals in the cohort whose blood samples showed low amino acid levels, high protein levels, and reduced phosphorylation of AMPKa threonine 172 (p-T172) in patients with Alzheimer's disease.
  • 50: The percentage of mice that developed AD-like symptoms when AMPKa2 was knocked out.
  • 5: The number of key regulators of protein synthesis identified in the study, including GCN2 and AMPK.
  • 2025: The year in which the study was published in Cell Metabolism.

Sources:

  • NewsRx. Reports from Huashan Hospital Highlight Recent Findings in Alzheimer Disease (AMPKa2 signals amino acid insufficiency to inhibit protein synthesis). Life Science Weekly. October 21, 2025; p 4582.
  • Cell Metabolism. AMPKa2 signals amino acid insufficiency to inhibit protein synthesis. Cell Metabolism, 2025.
  • Huashan Hospital, Shanghai, People's Republic of China. Department of Neurology, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, National Clinical Research Center for Aging and Medicine.